10-Q: Evolent Health Reports Q2 2026 Results: Revenue Up, But Losses Widen

Evolent Health, Inc. announced its second quarter 2026 financial results, showing a substantial increase in revenue but also a significant rise in operating expenses and a wider net loss.

Summary

• Evolent Health reported a 46.9% increase in revenue for the three months ended June 30, 2026, reaching $652.5 million, compared to $444.3 million in the prior year period.
• However, cost of revenue surged by 66.2% to $571.7 million, leading to an operating loss of $9.6 million for the quarter, a significant increase from the $1.2 million operating loss in Q2 2025.
• For the six-month period, revenue grew by 23.8% to $1.15 billion, while cost of revenue increased by 35.7% to $984.2 million, resulting in an operating loss of $20.2 million.
• The company's net loss attributable to common shareholders was $28.4 million for the quarter and $55.0 million for the six months ended June 30, 2026.
• Selling, general, and administrative expenses decreased by 8.5% for the quarter, primarily due to lower personnel costs and professional fees.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant increases in cost of revenue and a widening operating loss, despite revenue growth.

Positives

• Revenue increased significantly by 46.9% to $652.5 million for the three months ended June 30, 2026.
• Revenue for the six-month period increased by 23.8% to $1.15 billion.
• Selling, general, and administrative expenses decreased by 8.5% for the quarter, driven by cost control measures.
• The company maintains a strong liquidity position with $115.7 million in cash and cash equivalents as of June 30, 2026.

Negatives

• Cost of revenue increased substantially by 66.2% to $571.7 million for the three months ended June 30, 2026.
• Operating loss widened to $9.6 million for the quarter, compared to $1.2 million in the prior year.
• Medical Expense Ratio (MER) increased to 95.3% for both the quarter and the six-month period, indicating higher claims costs relative to revenue.
• Net loss attributable to common shareholders was $28.4 million for the quarter and $55.0 million for the six-month period.

Risks

• Significant portion of revenue derived from largest partners, with potential for loss, termination, or renegotiation.
• Increasing number of risk-sharing arrangements entered into with partners.
• Growth and success of partners are difficult to predict and subject to external factors like governmental funding reductions.
• Ability to accurately predict exposure under performance-based contracts.
• Dependency on key personnel and ability to attract, hire, integrate, and retain them.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures.
• Consolidation in the healthcare industry.
• Evolution of the healthcare regulatory and political framework.

Future Outlook

The company anticipates continued growth in the cost of treatment for cancer and cardiovascular patients, which they expect to be offset by contractual protections within their Performance Suite and the impact of their clinical interventions. Exchange membership attrition is expected to continue through the end of the year, though at a decreasing pace. Significant sustained inflation could negatively impact margins and profitability.

Management Comments

• We believe adherence to the best evidence supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.
• During 2024, the medical claims costs in our Performance Suite grew at a significantly faster rate than historical norms, negatively impacting our financial results.
• We believe these cost increases were industry-wide and not specific to Evolent.
• We anticipate continued growth in the cost of treatment for cancer and cardiovascular patients over time, which we expect to be offset by contractual protections within our Performance Suite and the impact of our clinical interventions.

Industry Context

StockSavvy.ai notes that Evolent Health operates in a challenging healthcare environment marked by rising medical claims costs, which appear to be an industry-wide trend. The company's performance is significantly influenced by the dynamics of health plan clients, particularly in the Medicaid and ACA Health Exchange markets, which are experiencing expected declines in membership and increased acuity.

Comparison to Industry Standards

• The Medical Expense Ratio (MER) for Evolent's specialty care management services solution increased to 95.3% for both the three and six months ended June 30, 2026, up from 80.0% and 73.6% respectively in the prior year periods. This significant increase suggests higher claims costs relative to revenue, potentially indicating a trend of rising medical costs impacting the broader healthcare payer and provider services industry.
• The company's revenue growth of 46.9% for the quarter and 23.8% for the six months, while strong, is being outpaced by the growth in cost of revenue (66.2% for the quarter, 35.7% for the six months), leading to a widening operating loss. This dynamic of revenue growth not keeping pace with cost increases is a concern across various sectors facing inflationary pressures and supply chain challenges, but is particularly acute in healthcare due to the direct impact of medical claims costs.

Legal Proceedings

• Shareholder derivative action filed regarding alleged negligence in oversight of relationship with Passport Health Plan; case was dismissed without prejudice, and a subsequent demand for litigation was refused by the Board.
• Received a Civil Investigative Demand (CID) from the DOJ concerning allegations related to unsupported diagnosis codes for Medicare Advantage beneficiaries, concerning a former customer; company is cooperating with the investigation.

Related Party Transactions

• Evolent has entered into services agreements with certain equity method investees to provide management, operational, and support services.
• Accounts receivable, prepaid expenses, accounts payable, and accrued liabilities include amounts attributable to related parties.

Stakeholder Impact

• Shareholders are impacted by the widening net loss and increased operating loss, potentially affecting stock value.
• Customers (health plans and risk-bearing entities) may be affected by the company's ability to manage costs and provide services effectively, especially given rising medical claims costs.
• Providers may be impacted by the company's performance-based arrangements and claims processing services.

Next Steps

• The company will continue to monitor the impact of inflation on its margins and profitability.
• Exchange membership attrition is expected to continue through the end of the year, though at a decreasing pace.
• The company may seek additional financing for investments, acquisitions, or expansion into other markets.

Key Dates

Recommendation

The filing indicates a worsening financial performance with significantly increased costs and operating losses, despite revenue growth. The rising Medical Expense Ratio and widening net loss suggest a deterioration in profitability that is concerning for investors. While revenue is growing, the inability to control costs and the increasing operational losses present a negative outlook.

Keywords

Evolent Health, Healthcare Services, Value-Based Care, Performance Suite, Specialty Care Management, Health Plan Operations, Claims Processing, Medical Expense Ratio